- Details
- Christopher Wallis and Zachary Klaassen discuss a publication entitled, “Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer”. Dr. Wallis discusses DNA damage repair mutations and how they present in men with localized prostate cancer. They also discuss the specific genomic mutations seen most commonly in men with DNA damage repair mutations affecting their prosta...
|
- Details
- Phillip Koo speaks with Masoom Haider about the potential of radiomics and machine learning in prostate cancer diagnosis and treatment. Dr. Haider explains that radiomics quantifies information in medical images, such as MRIs, to extract valuable data that can be analyzed using machine learning techniques. This could lead to better risk profiles for patients and more precise treatment plans. Howev...
|
- Details
- Matthew Cooperberg warmly welcomes Sanoj Punnen, to discuss the complexities surrounding the prediagnostic space for men with elevated PSA levels and the challenging decision of whether to pursue a biopsy. Dr. Punnen highlights the limitations of PSA as a screening tool, emphasizing the emerging role of liquid biopsy markers and MRI in this area. They both recognize the significance of integrating...
|
- Details
- Peter Gann and Adam Murphy join Ashley Ross to discuss how the use of the Genomic Prostate Score (GPS) may intersect with patient health literacy to affect decision-making regarding prostate cancer treatment. The discussion begins with an overview of genomics in prostate cancer, particularly the lack of validation of the Oncotype DX assay on African American men. From there, the conversation then...
|
- Details
- Andrew Winer and Ashley Ross engage in conversation about critical questions surrounding genomic testing and its impact on active surveillance and NCCN risk classification within the African American population. Dr. Winer points out that prostate cancer transforms into more clinically significant disease, grows faster, and often metastasizes earlier in African American men versus Caucasian men. He...
|
- Details
- Alicia Morgans sits down with Neal Shore to discuss the ENACT trial, which investigates the use of enzalutamide in patients starting on active surveillance for prostate cancer. Dr. Shore explains that the trial aims to address the underutilization of active surveillance and explores whether enzalutamide can prevent upstaging of histopathology and reduce positive biopsies. The study, which was not...
|
- Details
- At the 2022 EAU meeting, Declan Murphy presented the initial results of LuTectomy, a single-arm study of the dosimetry, safety, and potential benefit of 177Lu-PSMA-617 prior to radical prostatectomy. Biochemical recurrence rates remain very high for men undergoing either surgery or radiotherapy for localized prostate cancer and no neoadjuvant strategies have succeeded this far in changing that. In...
|
- Details
- Daniel Lin joins Alicia Morgans in highlighting a guideline-directed practical course on how to use genomics in clinical practice. Dr. Lin was part of the instructional course faculty at the AUA annual meeting. The learning objectives of this course include a discussion on the research studies that led to the approval of genomic testing for prostate cancer, ordering appropriate genomic testing bas...
|
- Details
- Matthew Cooperberg joins Alicia Morgans in a conversation on genomic risk classification in localized prostate cancer. They discuss the risk stratification of prostate cancer and where the use of this is most valuable. Dr. Cooperberg highlights this topic in terms of two basic categories of markers: the pre-diagnostic in terms of liquid tests and post-diagnostic settings. Biographies: Matthew Coop...
|
- Details
- Daniel Barocas joins Alicia Morgans in a conversation on the prospective population-based Comparative Effectiveness Analysis of Surgery And Radiation (CEASAR) study which assess rates and predictors of patient-reported treatment regret among men deciding on treatment for localized prostate cancer. The CEASAR Study began accruing patients in 2010 and has a population-based cohort of almost 3000 men...
|
